1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 36,600 | 41,800 | 08.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.12.25 | DUALITYBIO-B (09606): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 30, 2025 | 8 | HKEx | ||
| 08.12.25 | DUALITYBIO-B (09606): BOOK CLOSURE PERIOD FOR THE EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 17.10.25 | DUALITYBIO-B (09606): INSIDE INFORMATION - PROPOSED ISSUE OF RMB SHARES AND LISTING ON THE SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE | 2 | HKEx | ||
| 17.09.25 | DUALITYBIO-B (09606): 2025 INTERIM REPORT | 8 | HKEx | ||
| 05.09.25 | DUALITYBIO-B (09606): INSIDE INFORMATION - PRIMARY ENDPOINT MET FOR PHASE III CLINICAL TRIAL OF DB-1303/BNT323 IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE ... | 19 | HKEx | ||
| 26.08.25 | DUALITYBIO-B (09606): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 9 | HKEx | ||
| 14.08.25 | DUALITYBIO-B (09606): DATE OF BOARD MEETING | 1 | HKEx | ||
| 22.07.25 | Duality Biotherapeutics: DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation | 577 | PR Newswire | SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track... ► Artikel lesen | |
| DUALITY BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.07.25 | DUALITYBIO-B (09606): VOLUNTARY ANNOUNCEMENT - KEY PRODUCT DB-1310 GRANTED U.S. FDA FAST TRACK DESIGNATION | 2 | HKEx | ||
| 09.07.25 | Duality Biotherapeutics: First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 | 477 | PR Newswire | SHANGHAI, July 9, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing... ► Artikel lesen | |
| 05.06.25 | Duality Biologics: Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting | 678 | PR Newswire | SHANGHAI and CHICAGO, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the preliminary... ► Artikel lesen | |
| 23.05.25 | Duality Biotherapeutics: FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 | 224 | PR Newswire | Phase 1/2 first-in-human clinical study planned this year
SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606)... ► Artikel lesen | |
| 06.05.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 06.05.2025 | 767 | Xetra Newsboard | The following instruments on XETRA do have their first trading 06.05.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.05.2025
Aktien
1 KYG2929M1087 Duality Biotherapeutics... ► Artikel lesen | |
| 15.04.25 | Irrer Börsengang: BioNTech-Partner DualityBio explodiert am ersten Handelstag | 3.822 | Der Aktionär | Die Börse in Hongkong ist seit dem heutigen Mittwoch um ein Biotech-Unternehmen reicher. Duality Biotherapeutics (DualityBio) hat einen furiosen Start auf das Parkett gezaubert - nicht zuletzt dank... ► Artikel lesen | |
| 07.04.25 | Duality Biotherapeutics: Duality Bio Appoints Hua Mu as Global Chief Medical Officer | 505 | PR Newswire | SHANGHAI, April 7, 2025 /PRNewswire/ -- DualityBio announced today that Dr. Hua Mu has joined the company as Global Chief Medical Officer (CMO). In this role, Dr. Mu will oversee the strategic... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,60 | -1,34 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| MODERNA | 29,070 | -5,45 % | MODERNA: Heute ein Exot dank Impfstoff-Fortschritt. | Das Biotech-Unternehmen schafft heute eine Performance von aktuell + 9,7 %. Abgesehen vom zweiten "Exoten" AXON (+ 6,0 %), wird das Feld Top 10 klar von Halbleiter-Werten dominiert. Für den Antrieb... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 17,170 | -0,17 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,442 | +0,68 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,620 | -1,58 % | Piper Sandler and H.C. Wainwright Stay Bullish on CytomX (CTMX) | ||
| PRAXIS PRECISION MEDICINES | 294,38 | +0,63 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| APOGEE THERAPEUTICS | 77,48 | -1,85 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,830 | +0,73 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,880 | +1,01 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,350 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| VERA THERAPEUTICS | 47,690 | -2,03 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 23,280 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 25,310 | +8,72 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,570 | -1,93 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,000 | -3,21 % | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Resolution of Anemia... ► Artikel lesen |
DUALITY BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,61 % bei einem Aktienkurs von 37,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DUALITY BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.